Thioredoxin reductase (TrxR) plays an important role in the reduction of thioredoxin (Trx), which is found to be involved in the upregulation of a diversity of tumors, including those related to chemo-resistant tumors. In recent years, thioredoxin reductase (TrxR) has been identified as a very important regulator of tumor development, and therefore, targeting TrxR is a promising strategy for cancer therapy. The 3/2D-QSAR models were established in this study, such as HQSAR, and the study was based on CoMFA and CoMSIA analyses. The established optimal 2D-QSAR (HQSAR) model gave Q2 = 0.756, R2 = 0.959, and = 0.90, the established optimal CoMFA model gave Q2 = 0.671, R2 = 0.925, and = 0.853, and the CoMSIA/SEA model gave Q2 = 0.627, R2 = 0.962, and = 0.927. The predictive ability of the three proposed models was successfully evaluated using the criteria validation method of Golbraikh et al. [1] and Kunal Roy [2]. The visualization of the CoMFA contour map, the CoMSIA/SEA contour map, the HQSAR contribution map analysis, and the molecular docking results revealed that the R3 surrogate is important in enhancing or decreasing anti-cancer biological activity. Molecular dynamics (MD) simulation results revealed that both inhibitors remained stable in the active sites of the 3EAO protein for 100 ns. To propose new molecules based on a change in the R3 substituent, the three proposed models predicted the TrxR inhibitory activities of the four proposed new molecules, which were then evaluated using Lipinskiâ€™s rule, synthetic accessibility, and ADMET properties of each molecule. The obtained results have revealed that the compound C3 will be of great value as a new anti-cancer drug candidate.